Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 4 I, 2000, Pages 1229-1236

  Hasday, Jeffrey D ^a   Meltzer, Susan S ^b   Moore, Wendy C ^b   Wisniewski, Peter ^b   Hebel, J Richard ^b   Lanni, Carmine ^b   Dubé, Louise M ^b   Bleecker, Eugene R ^b  

^a BALTIMORE VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOTRIENE; ZILEUTON;

ADULT; AGED; AIRWAY RESISTANCE; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHOSCOPY; CLINICAL ARTICLE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATORY CELL; LUNG LAVAGE; MALE; MEDIATOR RELEASE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0034097177     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.4.9904026     Document Type: Article

References (25)

1. Drazen, J. M., E. Israel, and P. M. O'Byrne. 1999. Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 340: 197-206.
2. Israel, E., R. Dermarkarian, M. Rosenherg, R. Sperling, G. Taylor, P. Rubin, and J. M. Drazen. 1990. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N. Engl. J. Med. 323:1740-1744.
3. Meltzer, S. S., J. Hasday, J. Cohn, and E. R. Bleecker. 1996. Inhibition of exercise-induced bronchospasm by zileuton, a 5-lipoxygenase inhibitor. Am. J. Respir. Crit. Care Med. 153:931-935.
4. Israel, E., A. R. Fischer, M. A. Rosenberg, C. M. Lilly, J. C. Caller, J. Shapiro, J. Cohn, P. Rubin, and J. M. Drazen. 1993. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am. Rev. Respir. Dis. 148:1447-1451.
5. 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J. Allergy Clin. Immunol. 90: 193-201.
6. Kane, G. C., M. Pollice, C. J. Kim, R. T. Dworski, J. H. Murray, J. R. Sheller, J. E. Fish, and S. P. Peters. 1996. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J. Allergy Clin. Immunol. 97:646-654.
7. Abraham, W. M., A. Ahmed, A. Cortes, M. Sielczak, W. Hinz, J. Bouska, C. Lanni, and R. L. Bell. 1992. The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep. Eur. J. Pharmacol. 217:119-126.
8. Wenzel, S. E., J. B. Trudeau, D. A. Kaminsky, J. Cohn, R. J. Martin, and J. Y. Westcott. 1995. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am. J. Respir. Crit. Care Med. 152:897-905.
9. Calhoun, W. J., B. J. Lavins, M. C. Minkwitz, R. Evans, G. J. Gleich, and J. Cohn. 1998. Effect of zafirlukast (accolate) on cellular mediators of inflammation. Am. J. Respir. Crit. Care Med. 157:1381-1389.
10. DuBuske, L. M., J. Grossman, L. M. Dub, L. J. Swanson, and J. F. Lancaster. 1997. Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Am. J. Managed Care 3:633-640.
11. 4 and to methacholine in patients with asthma and normal controls. N. Engl. J. Med. 315: 480-484.
12. Wenzel, S. E., G. L. Larsen, K. Johnston, N. F. Voelkel, and J. Y. Westcott. 1990. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatic after endobronchial allergen challenge. Am. Rev. Respir. Dis. 142:112-119.
13. National Heart, Lung, and Blood Institute. 1997. Guidelines for the Diagnosis and Management of Asthma. Highlights of the Expert Panel Report II. National Institutes of Health, Bethesda, MD.
14. Chatham, M., E. R. Bleecker, P. L. Smith, R. R. Rosenthal, P. Mason, and P. S. Norman. 1982. A comparison of histamine, methacholine, and exercise airways reactivity in normal and asthmatic subjects. Am. Rev. Respir. Dis. 126:235-240.
15. National Heart, Lung, and Blood Institute. 1991. Workshop summary and guidelines: investigative use of bronchoscopy, lavage, and bronchial biopsies in asthma and other airway diseases. J. Allergy Clin. Immunol. 88:808-814.
16. Pradelles, P., J. Grassi, and J. Maclouf. 1990. Enzyme immunoassys of eicosanoids using acetylcholinesterase. In W. P. Colowick and N. O. Kaplan, editors. Methods of Enzymology. Academic Press, New York. 87.
17. Dubin, W. L., T. R. Martin, P. Swoveland, D. J. Leturcq, A. M. Moriarty, P. S. Tobias, E. R. Bleecker, S. E. Goldblum, and J. D. Hasday. 1996. Asthma and endotoxin: lipopolysaccharide-binding protein and soluble CD14 in the bronchoalveolar compartment. Am. J. Physiol. 270: L736-L744.
18. Wenzel, S. E. 1998. Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? No. Am. J Respir. Crit. Care Med. 158:1699-1701.
19. Diaz, P., M. C. Gonzalez, F. Galleguillos, P. Ancic, O. Cromwell, D. Shepherd, S. Durham, G. Gleich, and A. Kay. 1989. Leukocytes and mediators in bronchoalveolar lavage during allergen-induced latephase asthmatic reactions. Am. Rev. Respir. Dis. 139:1383-1389.
20. Sedgwick, J. B., W. J. Calhoun, G. J. Gleich, H. Kita, J. S. Abrams, L. B. Schwartz, B. Volovitz, M. Ben-Yaakov, and W. W. Busse. 1991. Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge: characterization of eosinophil and mast cell mediators. Am. Rev. Respir. Dis. 144:1274-1281.
21. 4. Proc. Natl. Acad. Sci. U.S.A. 79:7866-7870.
22. Scoggan, K. A., D. W. Nicholson, and A. W. Ford-Hutchinson. 1996. Regulation of leukotriene-biosynthetic enzymes during differentiation of myelocytic HL-60 cells to eosinophilic or neutrophilic cells. Eur. J. Biochem. 239:572-578.
23. Israel, E., P. Rubin, J. P. Kemp, J. Grossman, W. Pierson, S. C. Siegel, D. Tinkelman, J. J. Murray, W. Busse, A. T. Segal, et al. 1993. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern. Med. 119:1059-1066.
24. Fish, J. E., J. P. Kemp. R. F. Lockey, M. Glass, L. A. Hanby, and C. M. Bonuccelli. 1997. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clin. Ther. 19:675-690.
25. Broide, D. H., M. Lotz, A. J. Cuomo, D. A. Coburn, E. C. Federman, and S. I. Wasserman. 1992. Cytokines in symptomatic asthma airways. J. Allergy Clin. Immunol 89:958-967.